https://www.selleckchem.com/products/thz1.html
To determine the current role of bisantrene, an anthracene with anthracycline-like activity which was shown in earlier studies to be effective therapy in relapsed/refractory acute myeloid leukemia with no discernible cardiotoxicity, in the treatment of patients with R/R AML. This phase 2, single-center study (NCT03820908) enrolled adult R/R AML to receive bisantrene (250mg/m daily for 7days) which was administered via an intravenous infusion over 2hours on days 1-7. Disease assessment included routine blood work and bone marrow studies. In
Like
Comment
Share
